In conclusion, Tau-SAA in skin may contribute to a more accurate clinical diagnosis of tauopathies, and an optimized version of the assay can be extended to the analysis of skin samples in AD and for monitoring disease progression and efficacy of disease-modifying therapies. This evidence concerns the gene MAPT and Alzheimer disease.